Published in J Transl Med on September 03, 2012
Possible influence of B chromosomes on genes included in immune response and parasite burden in Apodemus flavicollis. PLoS One (2014) 1.38
Identification of male-specific amh duplication, sexually differentially expressed genes and microRNAs at early embryonic development of Nile tilapia (Oreochromis niloticus). BMC Genomics (2014) 0.98
Stroma as an Active Player in the Development of the Tumor Microenvironment. Cancer Microenviron (2014) 0.89
Cilia and coordination of signaling networks during heart development. Organogenesis (2013) 0.87
Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions. Stem Cells Dev (2014) 0.86
TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development. J Immunol Res (2014) 0.85
Growth factors in synaptic function. Front Synaptic Neurosci (2013) 0.85
TGFBI protein high expression predicts poor prognosis in colorectal cancer patients. Int J Clin Exp Pathol (2015) 0.85
Neuronal Rac1 is required for learning-evoked neurogenesis. J Neurosci (2013) 0.84
The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy. PLoS One (2014) 0.82
Cytoplasmic PML promotes TGF-β-associated epithelial-mesenchymal transition and invasion in prostate cancer. Oncogene (2015) 0.81
Complex temporal changes in TGFβ oncogenic signaling drive thyroid carcinogenesis in a mouse model. Carcinogenesis (2013) 0.81
Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. Neuro Oncol (2014) 0.81
Transforming growth factor (TGF)-β-induced microRNA-216a promotes acute pancreatitis via Akt and TGF-β pathway in mice. Dig Dis Sci (2014) 0.79
Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells. BMC Cancer (2015) 0.78
Analysis of consequences of non-synonymous SNP in feed conversion ratio associated TGF-β receptor type 3 gene in chicken. Meta Gene (2015) 0.78
Hypothyroidism and its rapid correction alter cardiac remodeling. PLoS One (2014) 0.78
The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol (2013) 0.78
Pro-tumorigenic effects of transforming growth factor beta 1 in canine osteosarcoma. J Vet Intern Med (2014) 0.78
Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p. Mol Cancer Res (2016) 0.78
Inhibitory Effect of Delphinidin on Extracellular Matrix Production via the MAPK/NF-κB Pathway in Nasal Polyp-Derived Fibroblasts. Allergy Asthma Immunol Res (2015) 0.77
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. J Clin Med (2016) 0.77
Effect of malaria components on blood mononuclear cells involved in immune response. Asian Pac J Trop Biomed (2013) 0.77
Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation. PLoS One (2016) 0.77
Shear-Sensitive Genes in Aortic Valve Endothelium. Antioxid Redox Signal (2016) 0.77
Transforming growth factor-β: an important mediator in Helicobacter pylori-associated pathogenesis. Front Cell Infect Microbiol (2015) 0.77
TGF-β3 Inhibits Antibody Production by Human B Cells. PLoS One (2017) 0.77
Signaling Pathways Related to Protein Synthesis and Amino Acid Concentration in Pig Skeletal Muscles Depend on the Dietary Protein Level, Genotype and Developmental Stages. PLoS One (2015) 0.77
Differential influence of inositol hexaphosphate on the expression of genes encoding TGF-β isoforms and their receptors in intestinal epithelial cells stimulated with proinflammatory agents. Mediators Inflamm (2013) 0.76
Modeling TGF-β in early stages of cancer tissue dynamics. PLoS One (2014) 0.76
Transforming growth factor-beta 1 delivery from microporous scaffolds decreases inflammation post-implant and enhances function of transplanted islets. Biomaterials (2015) 0.76
The Ability of Precursory Monocytes (MO) to Differentiate Varies Among Individuals But Is Stable Over Time. Med Sci Monit (2016) 0.76
Active transforming growth factor-β2 in the aqueous humor of posterior polymorphous corneal dystrophy patients. PLoS One (2017) 0.75
Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study. Radiol Oncol (2015) 0.75
Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms. MAbs (2015) 0.75
AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis. Oncotarget (2016) 0.75
Tgfbr2 is required in osterix expressing cells for postnatal skeletal development. Bone (2016) 0.75
Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling. J Biol Chem (2016) 0.75
TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Oncotarget (2016) 0.75
miR-320a functions as a suppressor for gliomas by targeting SND1 and β-catenin, and predicts the prognosis of patients. Oncotarget (2017) 0.75
Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget (2016) 0.75
Transcriptional factor EB regulates macrophage polarization in the tumor microenvironment. Oncoimmunology (2017) 0.75
Enamel and dental anomalies in latent-transforming growth factor beta-binding protein 3 mutant mice. Eur J Oral Sci (2017) 0.75
IL-25-induced activation of nasal fibroblast and its association with the remodeling of chronic rhinosinusitis with nasal polyposis. PLoS One (2017) 0.75
From Inflammation to Current and Alternative Therapies Involved in Wound Healing. Int J Inflam (2017) 0.75
TGF-β1 polymorphisms -509 C>T and +915 G>C and risk of pancreatic cancer. Gastroenterol Hepatol Bed Bench (2017) 0.75
Hierarchical patterning modes orchestrate hair follicle morphogenesis. PLoS Biol (2017) 0.75
Gene Regulation Network Based Analysis Associated with TGF-βeta Stimulation in Lung Adenocarcinoma Cells. Iran J Biotechnol (2017) 0.75
miR-202 Diminishes TGFbeta Receptors and Attenuates TGFbeta1-induced EMT in Pancreatic Cancer. Mol Cancer Res (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Smad transcription factors. Genes Dev (2005) 13.43
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
TGFbeta signaling in growth control, cancer, and heritable disorders. Cell (2000) 12.38
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A (1986) 12.14
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell (1999) 11.59
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature (1994) 10.95
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 10.82
Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol (2006) 10.74
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
SMAD proteins control DROSHA-mediated microRNA maturation. Nature (2008) 9.67
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev (1994) 8.52
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev (2000) 8.24
Mechanism of activation of the TGF-beta receptor. Nature (1994) 8.10
Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci U S A (1978) 8.01
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56
Autocrine secretion and malignant transformation of cells. N Engl J Med (1980) 7.49
Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell (2000) 6.69
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 6.43
The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell (1997) 6.34
Non-Smad TGF-beta signals. J Cell Sci (2005) 6.06
Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A (1985) 5.93
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A (1981) 5.89
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 5.84
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res (1995) 5.26
Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science (1984) 5.20
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 5.00
Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet (1995) 4.77
The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol (2002) 4.60
Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol (1989) 4.57
Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A (1995) 4.54
SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell (1998) 4.51
Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet (1995) 4.46
Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer (2008) 4.43
A human Mad protein acting as a BMP-regulated transcriptional activator. Nature (1996) 4.36
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol (1988) 4.34
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev (2008) 4.25
Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem (2001) 4.22
Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A (2001) 4.20
A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature (1999) 4.17
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell (1996) 4.13
Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev (2005) 4.05
Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem (1988) 3.98
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell (2002) 3.87
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J (2002) 3.80
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell (1996) 3.73
Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem (1992) 3.57
A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell (2003) 3.57
The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell (1987) 3.52
Betaglycan presents ligand to the TGF beta signaling receptor. Cell (1993) 3.48
Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol (2007) 3.47
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res (1999) 3.40
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell (2007) 3.27
Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev (1998) 3.16
Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell (2010) 3.12
Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol Cell (2002) 3.10
p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci (2002) 3.07
Receptors for the TGF-beta family. Cell (1992) 3.00
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99
TGF-beta receptor signaling. Biochim Biophys Acta (1997) 2.99
Smads as transcriptional co-modulators. Curr Opin Cell Biol (2000) 2.92
Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89
The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev (1998) 2.82
Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol (1993) 2.81
TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol (2003) 2.68
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev (2003) 2.58
Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem (1999) 2.56
Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A (2001) 2.55
How the Smads regulate transcription. Int J Biochem Cell Biol (2007) 2.46
Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev (2006) 2.46
Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol (1996) 2.44
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev (1997) 2.35
Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res (1992) 2.29
Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology (1996) 2.28
Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology (2000) 2.27
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol (2006) 2.27
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J (1987) 2.23
Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal (2006) 2.22
Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2006) 2.20
The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature (1998) 2.18
Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol (1993) 2.16
Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol (1994) 2.15
Two forms of transforming growth factor-beta distinguished by multipotential haematopoietic progenitor cells. Nature (1987) 2.13
Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev (1999) 2.12
Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A (2010) 2.07
Identification of another member of the transforming growth factor type beta gene family. Proc Natl Acad Sci U S A (1988) 2.07
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest (2006) 2.06
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood (2008) 2.12
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol (2013) 1.99
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol (2010) 1.38
Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica (2013) 1.22
Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol (2010) 1.20
Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med (2010) 1.15
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol (2012) 1.10
Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One (2012) 1.09
Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations. Med Oncol (2002) 1.08
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma (2011) 0.96
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res (2013) 0.94
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med (2014) 0.92
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma (2012) 0.92
Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol (2009) 0.90
Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int J Colorectal Dis (2012) 0.90
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol (2012) 0.90
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica (2013) 0.89
Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma (2012) 0.88
Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One (2012) 0.88
PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica (2012) 0.87
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica (2011) 0.87
Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res (2012) 0.86
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant (2010) 0.86
MyelomA Genetics International Consortium. Leuk Lymphoma (2012) 0.86
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica (2010) 0.85
Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Leuk Res (2006) 0.85
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma (2008) 0.85
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma (2009) 0.84
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica (2011) 0.84
Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom (2013) 0.83
Proteomic analysis in multiple myeloma research. Mol Biotechnol (2011) 0.83
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk (2013) 0.82
Interdigitating dendritic cell sarcoma of the leg. Onkologie (2009) 0.81
Comparison of functional fibrinogen assessment using thromboelastography with the standard von Clauss method. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2011) 0.81
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse. Clin Lymphoma Myeloma (2009) 0.80
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk (2011) 0.79
Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leuk Lymphoma (2013) 0.79
Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer. Nutr Cancer (2013) 0.79
Detection and long-term in vivo monitoring of individual tumor-specific T cell clones in patients with metastatic melanoma. J Immunol (2007) 0.79
Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine (2003) 0.78
Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med (2013) 0.78
High frequency of temperature-sensitive mutants of p53 in glioblastoma. Pathol Oncol Res (2013) 0.78
Shared structural features of the 9aaTAD family in complex with CBP. Mol Biosyst (2015) 0.78
Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom (2013) 0.78
Bone marrow plasma cell separation - validation of separation algorithm. Clin Chem Lab Med (2012) 0.78
1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leuk Lymphoma (2012) 0.77
Association of aneuploidy category with centrosome amplification in multiple myeloma. Leuk Lymphoma (2011) 0.77
Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. Oncoimmunology (2013) 0.77
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leuk Res (2013) 0.77
Results of therapy and changing prognosis of multiple myeloma during the last 40 years in the region of North and Middle Moravia: group of 562 patients. Hematol J (2003) 0.77
Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. Am J Hematol (2015) 0.77
Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology (2003) 0.77
Skin lesions induced by bortezomib. Haematologica (2005) 0.77
Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin Lymphoma Myeloma Leuk (2011) 0.76
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. Hematol J (2005) 0.76
Nestin expression throughout multistep pathogenesis of multiple myeloma. Br J Haematol (2013) 0.76
Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. Br J Haematol (2010) 0.76
Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics (2013) 0.76
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Ann Hematol (2011) 0.75
Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma. Ann Hematol (2009) 0.75
Vacuum-assisted closure in the treatment of sternal wound infection after cardiac surgery. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2007) 0.75
Bone marrow plasma cell separation - validation of separation algorithm. Clin Chem Lab Med (2012) 0.75
Measurement of the flow in coronary artery bypass grafts. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2006) 0.75
Accidental deep hypothermia with cardiac arrest. Prompt complete recovery after rewarming by extracorporeal circulation. Case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2007) 0.75
Sequential bypass grafting on the beating heart: blood flow characteristics. Ann Thorac Surg (2006) 0.75